


## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Applicant:</b> GEORG BALJER et al.	<b>Examiner:</b>
<b>Serial No.:</b> 10/009,059	<b>Group Art Unit:</b>
<b>Filed:</b> December 3, 2001	<b>Docket No.</b> 20740-242738
<b>For:</b> RECOMBINANT FUSION PROTEIN, (VACCINE) COMPOSITION CONTAINING THE SAME AND METHOD FOR THE PRODUCTION THEREOF	

Commissioner for Patents  
Washington, D.C. 20231

I CERTIFY THAT, ON FEBRUARY 28, 2002, THIS PAPER IS BEING  
DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN  
AN ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS,  
WASHINGTON, D.C. 20231.

  
Kimberly L. Bzdek

## INFORMATION DISCLOSURE STATEMENT

The documents listed on the enclosed Form PTO-1449 are presented pursuant to Applicant's duty of disclosure under 37 C.F.R. § 1.56. These documents were identified in the attached International Search Report, a copy which is attached hereto. Further attached are the following foreign patents: DE 42 19 696 and FR 2 766 193 as well as the following entitled articles:

1. Expression of A and B Subunits of Shiga-Like Toxin II as Fusions with Glutathione S- Transferase and Their Potential For Use in Seroepidemiology;
2. Construction of recombinant Shiga-like toxin-IIv (SLT-IIv) and its use in monitoring the SLT-IIv antibody status of pigs;
3. Expression and Purification of Shiga-Like Toxin II B Subunits;
4. Untersuchungen zur Immunantwort bei der Ödemkrankheit von Absetzferkeln mit einer rekombinanten B-Untereinheit des Shiga-like-Toxins-II

10/009,059

02/28/02


Page 2

No fee is believed to be necessary for the entry of this Information Disclosure Statement. Should any fee be required, the Commissioner is authorized to charge our Deposit Account No. 06-0029 and notify us of the same.

Respectfully Submitted,

GEORG BALJER et al.

By:

  
Paul W. Busse, #32,403  
FAEGRE & BENSON LLP  
2200 Wells Fargo Center  
90 South Seventh Street  
Minneapolis, MN 55402-3901  
612/766-7046

Dated: February 28, 2002

M2:20446137.01

February 28, 2002

Page 1 of 1

Form PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

Serial No.

20740-242738

10/009,059

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant

GEORG BALJER et al.

Filing Date

Group

December 3, 2001

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Name	Document Number	Date	Country	Class	Subclass	Translation Yes/No
	✓	WO 98 11229 A	3/19/1998				
	-	WO 96 30043 A	10/3/1996				
		WO 97 31117	8/28/1997				
		WO 96 12802	5/2/1996				
	-	DE 42 19 696 A1	8/19/1993				
	-	FR 2 766 193 A1	1/22/99				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Expression of A and B Subunits of Shiga-Like Toxin II as Fusions with Glutathione S-Transferase and Their Potential For Use in Seroepidemiology; Gunzer, Florian; Karch, Helge; 29 June 1993, pp. 2604-2610.
			Construction of recombinant Shiga-like toxin-IIv (SLT-IIv) and its use in monitoring the SLT-IIv antibody status of pigs; Franke, Sylvia; Gunzer, Florian; Wieler, Lothar H.; Baljer, Georg; Karch, Helge; 3 May 1994; pp. 41-52.
			Expression and Purification of Shiga-Like Toxin II B Subunits; Acheson, David W. K.; De Breuker, Sabine A; Jacewicz, Mary; Lincicome, Lisa L.; Donohue-Rolfe, Arthur; Kane, Anne V.; Keusch, Gerald T.; 12 October 1994; Vol. 63, pp. 301-308.
			Untersuchungen zur Immunantwort bei der Ödemkrankheit von Absetzferkeln mit einer rekombinanten B-Untereinheit des Shiga-like-Toxins-II; Wieler, Von L. H.; Franke, Sylvia; Menge, Ch.; Rose, M.; Bauerfeind, R.; Karch, H; Baljer, G.; 1995; pp. 40-43.

Examiner

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.